Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, Feb 1995, 394-399, Vol 39, No. 2
JC Fung-Tomc, E Huczko, J Banville, M Menard, B Kolek, E Gradelski, RE Kessler and DP Bonner
A number of carbapenem derivatives were examined to determine the
structure-activity relationships required for dependence on porin protein
D2 for activity against Pseudomonas aeruginosa. As suggested by J. Trias
and H. Nikaido (Antimicrob. Agents Chemother. 34:52-57, 1990), carbapenem
derivatives, such as imipenem and meropenem, containing a sole basic group
at position 2 of the molecule utilize the D2 channel for permeation through
the outer membrane of pseudomonads; they are more active against
D2-sufficient strains of P. aeruginosa. Our results indicated that
carbapenems with a basic group at position 1 or 6 of the molecule did not
depend on the D2 channel for activity; i.e. they were equally active
against D2-sufficient and D2-deficient pseudomonal strains. However,
addition of a basic group at position 1 or 6 of a carbapenem derivative
already containing a basic group at position 2 resulted in its lack of
dependency on the D2 pathway. Comparison between meropenem and its
1-guanidinoethyl derivative, BMY 45047, indicated that they differed in
their dependence on D2; while meropenem required the D2 channel for uptake,
BMY 45047 activity was independent of D2. Meropenem and BMY 45047 had
similar affinities for the penicillin-binding proteins of P. aeruginosa.
However, BMY 45047 and meropenem differed in the morphological changes that
they induced in pseudomonal cells. While meropenem induced filamentation,
BMY 45047 induced filaments only in BMS-181139-resistant mutants and not in
imipenem-resistant mutants or in carbapenem-susceptible P. aeruginosa
strains.(ABSTRACT TRUNCATED AT 250 WORDS)
Copyright © 1995 by the American Society for Microbiology. All rights reserved.
Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»